Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | TK2 | O00142 | 5/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivudine SCHEMBL13030272 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4283383 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL4314668 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL141407 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL13674189 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL1172398 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL99350 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL5983819 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL21316784 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM | |
| Brivudine SCHEMBL15405329 | 1.00 | TK1 (1.00) | TK1CYP1A2CYP3A4TSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | REDHILL BIOPHARMA LTD (IL) | 2021-12-02 | — | — | US | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2020-01-28 | — | — | US | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-9974800-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2018-05-22 | — | — | US | disclosed |
| US-9974800-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2018-05-22 | — | — | US | disclosed |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | NANJING MOLECULAR RESEARCH, INC. (CN) | 2013-08-15 | — | — | US | disclosed |
| EP-1898935-B1 | NORTH-2'-DEOXY-METHANOCARBATHYMIDINES AS ANTIVIRAL AGENTS AGAINST POXVIRUSES | US GOV HEALTH & HUMAN SERV (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| WO-2009129094-A2 | COMPOSITIONS CONTAINING ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | MALLINCKRODT INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | TK1 732/4885CYP1A2 3115/4885CYP3A4 1281/4885 |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | RNMT, EIF2AK2, POLRMT | TK1 451/4885CYP1A2 4681/4885CYP3A4 4538/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | TK1 385/4885CYP1A2 4267/4885CYP3A4 4417/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | TK1 1425/4885CYP1A2 4500/4885CYP3A4 4212/4885 |
| US-20090221523-A1 | North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses | SAMHD1, TK2, DCTD | TK1 62/4885CYP1A2 1717/4885CYP3A4 2432/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | TK1 1878/4885CYP1A2 344/4885CYP3A4 239/4885 |
| US-20130210757-A1 | DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS | PNP, PAICS, NTPCR | TK1 34/4885CYP1A2 1048/4885CYP3A4 922/4885 |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | SPHK2, SPHK1, S1PR2 | TK1 385/4885CYP1A2 4267/4885CYP3A4 4417/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | TK1 2512/4885CYP1A2 437/4885CYP3A4 199/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | TK1 1425/4885CYP1A2 4500/4885CYP3A4 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.